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EDITORIAL
Why we block angiotensin II
Current use of angiotensin II (Ang II) blocking agents and activity of the oxidant-inducible enzyme, heme oxy-
to slow renal disease progression provides an example genase.
of successful interaction between laboratory and clinical Having identified increased oxidative stress in the kid-
investigation. Studies showing that converting enzyme neys of Ang II-treated rats, Haugen et al attempted to
inhibitors prevented remnant glomerular injury in rats dissect the association between angiotensin II, oxidative
with reduced nephron number prompted trials of these stress, and injury [2]. They approached this problem with
agents in patients with renal insufficiency [1]. The success unusual care. First, they addressed the question of
of these trials in turn has stimulated further studies of whether oxidative stress is caused directly by Ang II or
the role of Ang II in experimental disease. The goal of whether it is a secondary consequence of renal injury.
these studies, as exemplified by the work of Haugen, Studies in the DOCA salt model showed that oxidative
Croatt and Nath, reported in this issue, is to improve stress is not a common consequence of renal injury char-
clinical therapy [2]. Hopefully, reciprocating analysis of acterized by glomerular hypertension and proteinuria.
clinical and experimental data will steadily enhance our Studies in cultured cells showed that Ang II increases
ability to treat progressive renal diseases. heme oxygenase expression. The demonstration that
How can the current round of experimental studies Ang II infusion in vivo causes oxidative stress before
guide future clinical efforts? One way is to provide a renal injury becomes apparent would have been a desir-
more logical basis for the prescription of Ang II blocking able supplement to these studies. Even without such a
drugs. Trials in clinical renal disease for the most part demonstration, however, one is inclined to accept the
have employed drug doses shown effective in essential authors’ conclusion that Ang II causes oxidative stress.
hypertension. Better understanding of the actions of Ang Having found that Ang II causes oxidative stress, the
II in diseased kidneys might prompt trials of higher doses authors addressed the more difficult question of whether
in some patients. Given the potential hazards of higher oxidative stress contributes to injury. They would like
doses and the logistic demands of human trials, investiga- to have determined whether preventing oxidative stress
tors reasonably may hesitate to undertake such trials protects the kidney from Ang II-induced injury. Thera-
without more experimental data to guide their design. pies to reduce oxidative stress, however, are limited. The
Experimental studies of Ang II action also may guide authors therefore instead assessed the effect of a pro-
future clinical efforts by identifying new targets for thera- oxidant diet. Their finding that this maneuver increased
peutic intervention. Two general strategies have been injury is consistent with the hypothesis that oxidative
employed for this purpose. The first is to treat animals stress causes injury. However, it does not tell us how
or cultured cells with Ang II blocking agents and see much of the Ang II-induced renal injury is attributable
what processes are suppressed. The second, as employed to oxidative stress, or whether Ang II blocking agents
by Haugen et al, is to administer Ang II and see what protect the kidney by reducing oxidative stress.
processes are stimulated [2]. In essence, these authors The problem faced by Haugen et al in establishing the
began with the knowledge that Ang II causes renal in- importance of a potential mechanism of Ang II-induced
jury, and sought to find out how it does so. As is often injury is encountered in all studies that examine the role
the case in studies of renal disease, they were guided of Ang II in renal disease [2]. Ang II increases systemic
by recent developments in the larger field of vascular and glomerular capillary pressure. It also acts directly
biology. The finding that Ang II causes oxidative stress on renal cell types including smooth muscle cells, glomer-
in smooth muscle cells prompted them to investigate ular epithelial cells, and tubular epithelial cells. There is
whether Ang II causes a similar change in the kidney. evidence that both the hemodynamic and the direct,
They found that kidneys from rats given a dose of Ang II cellular effects of Ang II can promote injury culminating
sufficient to cause hypertension and proteinuria exhibit in fibrotic renal disease [3, 4]. At present, one can argue
increased lipid peroxidation, protein carbonyl content, in favor of the importance of one or another mechanism
of injury based on the time course and ubiquity of
changes observed in different disease models. However,Key words: progressive renal disease, oxidative stress, hypertension,
kidney injury. rigorous demonstration of the importance of any of the
individual effects of Ang II is not possible because AngÓ 2000 by the International Society of Nephrology
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II blocking drugs counteract all of them. The develop- by infusing Ang II and, in many cases, reduce renal injury
by blocking Ang II. We therefore use Ang II to get ament of animals in which elements of the renin-angio-
tensin system can be deleted locally in a controlled man- handle on other potential mediators of injury. If a process
such as oxidant stress is increased by Ang II and reducedner offers exciting hope of better understanding in the
future [5]. by Ang II blockade, our interest in it increases. In the
end, of course, we want to know more about the processIn discussing any study of the mechanism(s) by which
Ang II injures the kidney, it is worth remembering that than how Ang II effects it. In particular, we want to know
what happens when we block the process selectively. Wewe have little evidence that Ang II levels are increased
in kidney disease. Circulating renin and angiotensin lev- hope that studies in which Ang II is manipulated, such
as the one performed by Haugen et al [2], will help guideels are not increased in rats with a reduced nephron
number, though Ang II blockade has been repeatedly the development of more powerful pharmacologic and
genetic interventions to slow the progression of renalshown to protect against disease progression in these
animals [6]. Of course it is possible that Ang II blockade disease.
works by counteracting an increase in Ang II concentra-
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